SGX:H02Pharmaceuticals
Haw Par (SGX:H02) Is Down 7.0% After EPS Rises Despite Weaker Sales – Has The Bull Case Changed?
Haw Par Corporation Limited has released its full-year 2025 results, reporting sales of S$229.97 million versus S$244.82 million a year earlier, while net income rose to S$265.46 million from S$228.27 million and basic earnings per share from continuing operations increased to S$1.199 from S$1.031.
Despite lower sales, Haw Par’s stronger net income and higher earnings per share indicate that margins or other income sources have supported profitability.
Next, we will examine how Haw Par’s...